Innate Pharma SA
PAR:IPH
Intrinsic Value
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight... [ Read More ]
The intrinsic value of one IPH stock under the Base Case scenario is 6.12 EUR. Compared to the current market price of 2.41 EUR, Innate Pharma SA is Undervalued by 61%.
Valuation Backtest
Innate Pharma SA
Run backtest to discover the historical profit from buying and selling IPH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Innate Pharma SA
Current Assets | 148m |
Cash & Short-Term Investments | 92.5m |
Receivables | 46.5m |
Other Current Assets | 9.1m |
Non-Current Assets | 36.2m |
Long-Term Investments | 9.8m |
PP&E | 6.3m |
Intangibles | 416k |
Other Non-Current Assets | 19.6m |
Current Liabilities | 39.6m |
Accounts Payable | 25.6m |
Accrued Liabilities | 7m |
Short-Term Debt | 7.1m |
Other Current Liabilities | -54k |
Non-Current Liabilities | 92.7m |
Long-Term Debt | 76m |
Other Non-Current Liabilities | 16.7m |
Earnings Waterfall
Innate Pharma SA
Revenue
|
51.9m
EUR
|
Cost of Revenue
|
-2.9m
EUR
|
Gross Profit
|
49m
EUR
|
Operating Expenses
|
-61.7m
EUR
|
Operating Income
|
-12.7m
EUR
|
Other Expenses
|
5.1m
EUR
|
Net Income
|
-7.6m
EUR
|
Free Cash Flow Analysis
Innate Pharma SA
IPH Profitability Score
Profitability Due Diligence
Innate Pharma SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Innate Pharma SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
IPH Solvency Score
Solvency Due Diligence
Innate Pharma SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Innate Pharma SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IPH Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IPH is 6.71 EUR with a low forecast of 2.27 EUR and a high forecast of 13.65 EUR.
Shareholder Return
IPH Price
Innate Pharma SA
Average Annual Return | -8.69% |
Standard Deviation of Annual Returns | 33.48% |
Max Drawdown | -73% |
Market Capitalization | 194.8m EUR |
Shares Outstanding | 80 841 988 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
Contact
IPO
Employees
Officers
The intrinsic value of one IPH stock under the Base Case scenario is 6.12 EUR.
Compared to the current market price of 2.41 EUR, Innate Pharma SA is Undervalued by 61%.